Articles From: SapientNitro’s Second Story Helps Vornado Realty Trust Launch Largest Interactive Advertising Display in the World to Sarepta Therapeutics to Host Webcast and Conference Call for the Duchenne Muscular Dystrophy Community on December 2, 2014


Second Story, part of SapientNitro (NASDAQ: SAPE), today announced that it has been engaged by Vornado Realty Trust to help unveil the largest LED advertising display in the world.
Sign-up for SapientNitro’s Second Story Helps Vornado Realty Trust Launch Largest Interactive Advertising Display in the World investment picks
Second Story, part of SapientNitro (NASDAQ: SAPE), today announced the launch of four interactive experiences it created for Whole Foods Market’s new Alpharetta store, in the Avalon planned mixed-use development.
Sign-up for SapientNitro’s Second Story Helps Whole Foods Market Innovate the Shopping Experience in New Alpharetta, GA Store investment picks
2014/12/9
By Jason Ng KUALA LUMPUR--SapuraKencana Petroleum Bhd (5218.KU), Malaysia's largest oil-and-gas services firm by market value, said Tuesday net profit surged 42% in the fiscal third quarter thanks to higher income from its drilling and energy services business.
Sign-up for SapuraKencana 3rd-Quarter Net Surges 42% on Year investment picks
2014/11/20
By Wayne Ma SapuraKencana Petroleum Bhd.
Sign-up for SapuraKencana Petroleum: Enters Into Production-Sharing Contract With Petronas investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0978175001&sourceType=1 http://www.ccnmatthews.com/logos2/saputo.gif MONTREAL, QUEBEC --
Sign-up for Saputo Inc. Announces that Two Rating Agencies, DBRS and Moody's, Have Assigned Ratings investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0977532001&sourceType=1 http://www.ccnmatthews.com/logos2/saputo.gif MONTREAL, QUEBEC --
Sign-up for Saputo Inc.: Financial Results for Fiscal 2015 Second Quarter Ended September 30, 2014 investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0972757001&sourceType=1 http://www.ccnmatthews.com/logos2/saputo.gif MONTREAL, QUEBEC --
Sign-up for Saputo Inc.: Fiscal 2015 Second Quarter Results investment picks
Hawker Energy, Inc. (OTCQB:HWKR) (the “Company”) is pleased to announce it has changed its name from Sara Creek Gold Corp.
Sign-up for Sara Creek Gold Corp. Announces Name and Ticker Symbol Change to Hawker Energy, Inc. (OTCQB:HWKR) investment picks
2014/10/8
Save room for dessert! Today two new flavors join the iconic Sara Lee ® Desserts pound cake product line: Blueberry Pound Cake and Gingerbread Pound Cake.
Sign-up for Sara Lee® Desserts Sweetens Pound Cake Portfolio with Two New Flavors investment picks
2014/10/6
Sarah McLachlan School of Music hits high note with $300,000 donation from Sun Life Financial Canada NewsWire VANCOUVER , Oct.
Sign-up for Sarah McLachlan School of Music hits high note with $300,000 donation from Sun Life Financial investment picks
The Premier Hospital in the Upstate New York Region Selects Omnicell Solutions to Help Improve Nurse, Pharmacy Workflow and Enhance Patient Safety MOUNTAIN VIEW, Calif.
Sign-up for Saratoga Hospital Selects Omnicell Unity Enterprise Platform to Upgrade Existing Medication Automation Solutions investment picks
Stockholders Must Notify their Brokers by November 25th if they Prefer their Dividend in Shares of Common Stock NEW YORK , Nov.
Sign-up for Saratoga Investment Corp. Comments on Recently Announced Dividend and Dividend Reinvestment Plan investment picks
Also Announces Dividend Reinvestment and Share Repurchase Plan NEW YORK , Sept.
Sign-up for Saratoga Investment Corp. to Pay Regular Cash Dividend investment picks
Computer scientists at Lawrence Livermore National Laboratory (LLNL) have combined innovative research in graph algorithms and data-intensive runtime systems to achieve world-class results on the Graph500 benchmark ( www.graph500.org ). The scientists’ work has been enabled by leading edge technology supplied by Saratoga Speed, Inc. and Mellanox® Technologies, Ltd.
Sign-up for Saratoga Speed and Mellanox Technologies Help Lawrence Livermore Lower the Barrier of Entry for Large Scale Graph Analytics investment picks
2014/10/27
A Piper Jaffray equity analyst cut his price target on Sarepta Therapeutics Inc. (SRPT) Monday.
Sign-up for Sarepta price target slashed by Piper Jaffray investment picks
Sarepta Therapeutics Inc. (SRPT) shares climbed 4% after hours Thursday as the company said an Ebola drug it is testing has shown no clinically significant side effects.
Sign-up for Sarepta says it sees no side effects from Ebola drug investment picks
By Russ Britt, MarketWatch As a handful of drug makers jockeyed for a profitable position in the nascent industry rising up to fight Ebola, Sarepta Therapeutics Inc. vied for the spotlight Thursday by announcing positive test results from human tests of an antidote.
Sign-up for Sarepta says its Ebola drug has no ill effects investment picks
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today announced favorable safety results from the single ascending dose portion of a Phase I study of AVI-7100, the company’s lead candidate for the treatment of influenza virus, in healthy volunteers.
Sign-up for Sarepta Therapeutics Announces Favorable Safety Results from Phase I Clinical Study of Influenza Drug Candidate investment picks
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of RNA-based therapeutics today announced that it has initiated dosing in a confirmatory study of eteplirsen, the Company’s lead exon-skipping therapeutic candidate for the treatment of Duchenne muscular dystrophy (DMD), in ambulatory patients who meet specific criteria on their baseline 6-minute walk test score.
Sign-up for Sarepta Therapeutics Announces First Patient Dosed in Confirmatory Study of Eteplirsen in Ambulant Patients with Duchenne Muscular Dystrophy investment picks
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of RNA-based therapeutics, today announced that it has initiated dosing in a clinical study of eteplirsen, the Company's lead exon-skipping therapeutic candidate for the treatment of Duchenne muscular dystrophy (DMD), in patients who are non-ambulant or who have advanced DMD and don't meet a minimum 6-minute walk test score at baseline.
Sign-up for Sarepta Therapeutics Announces First Patient Dosed in Study of Eteplirsen in Non-Ambulant Patients with Duchenne Muscular Dystrophy investment picks
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-based therapeutics, today announced that it will give one oral presentation and two poster presentations on data from its ongoing Phase II and preclinical trials evaluating exon-skipping therapies for the treatment of Duchenne muscular dystrophy (DMD) at the International Congress of the World Muscle Society (WMS), being held from October 7-11, 2014, in Berlin, Germany.
Sign-up for Sarepta Therapeutics Announces Presentations at the 19th International Congress of the World Muscle Society investment picks
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today announced the publication of results from two single ascending-dose studies that demonstrated no clinical or toxicologic safety concerns with the company’s drug candidates for the treatment of Ebola and Marburg virus, respectively.
Sign-up for Sarepta Therapeutics Announces Publication of Ebola and Marburg Phase I Clinical Study Results in Antimicrobial Agents and Chemotherapy investment picks
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-based therapeutics, today provided an update on its discussions with the U.S. Food and Drug Administration (FDA) regarding its planned New Drug Application (NDA) submission for the approval of eteplirsen for the treatment of Duchenne muscular dystrophy (DMD). In meeting minutes received last week from a Type B Pre-NDA meeting that took place in September 2014, the FDA provided updated guidance regarding the specific data to be included as part of, or at the time of, Sarepta’s NDA submission.
Sign-up for Sarepta Therapeutics Announces Regulatory Update on Eteplirsen investment picks
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today reported financial results for the three and nine months ended September 30, 2014, and provided an update of recent corporate developments.
Sign-up for Sarepta Therapeutics Announces Third Quarter 2014 Financial Results and Recent Corporate Developments investment picks
2014/10/1
On the heels of news of the first case of Ebola on U.S. soil, the company that has developed a treatment for the deadly disease said it has enough doses to cover about 100 patients.
Sign-up for Sarepta Therapeutics CEO: We have just 100 doses to treat Ebola investment picks
By Erin McCarthy Sarepta Therapeutics Inc. said the U.S. Food and Drug Administration is requiring additional data for the new drug application for its Duchenne muscular dystrophy treatment eteplirsen.
Sign-up for Sarepta Therapeutics sees setback in Eteplirsen drug application investment picks
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, will report third quarter 2014 financial results before the NASDAQ Global Market opens on Thursday, November 6, 2014.
Sign-up for Sarepta Therapeutics to Announce Third Quarter 2014 Financial Results and Corporate Update on November 6, 2014 investment picks
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, will host a webcast and conference call for the Duchenne muscular dystrophy (DMD) community on Tuesday, December 2, 2014, beginning at 11:00 a.m. EST (8:00 a.m. PST / 4:00 p.m. GMT / 5:00 p.m. CET). Chris Garabedian, president and chief executive officer, and Edward Kaye, M.D., chief medical officer, will provide information and answer questions about Sarepta's DMD development program, including current and upcoming clinical trials.
Sign-up for Sarepta Therapeutics to Host Webcast and Conference Call for the Duchenne Muscular Dystrophy Community on December 2, 2014 investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: SapientNitro’s Second Story Helps Vornado Realty Trust Launch Largest Interactive Advertising Display in the World to Sarepta Therapeutics to Host Webcast and Conference Call for the Duchenne Muscular Dystrophy Community on December 2, 2014
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent